Jardiance (Empagliflozin) is Safe and May Actually Reduce Kidney Stone Risk
Yes, Jardiance is safe for patients with a history of kidney stones, and emerging evidence suggests it may actually help prevent stone recurrence. There are no contraindications or warnings in the FDA label regarding kidney stones 1, and recent high-quality research demonstrates that empagliflozin reduces kidney stone formation risk.
Key Evidence Supporting Safety and Potential Benefit
Direct Stone Prevention Data
A 2025 randomized controlled trial specifically studied empagliflozin in nondiabetic patients with kidney stones and found remarkable results 2:
- For calcium stone formers: Empagliflozin reduced calcium phosphate supersaturation by 36% (p<0.001)
- For uric acid stone formers: Empagliflozin reduced uric acid supersaturation by 30% (p=0.002)
- No serious adverse events occurred in this stone-former population
- These supersaturation ratios are validated surrogates for stone recurrence risk
A 2022 pooled analysis of 15,081 patients from 20 clinical trials showed empagliflozin reduced urinary tract stone events by approximately 40% compared to placebo (incidence rate ratio 0.64,95% CI 0.48-0.86) 3.
Mechanism of Benefit
Empagliflozin likely reduces stone risk through:
- Altered urinary lithogenic profile (reduced supersaturation of stone-forming crystals)
- Increased urinary flow from osmotic diuresis
- Changes in urinary pH and electrolyte composition
Safety Considerations Specific to Your Patient
No Stone-Related Contraindications
The FDA label contains no warnings or precautions regarding kidney stone history 1. The contraindications are limited to:
- Dialysis patients
- Serious hypersensitivity reactions
Monitor for Standard SGLT2 Inhibitor Effects
While kidney stones are not a concern, monitor for:
- Volume depletion: Particularly if patient is elderly (≥75 years) or on diuretics 1
- Urinary tract infections: Slightly increased risk (though this did not occur more frequently in the stone-former trial) 2
- Renal function: Ensure eGFR ≥20 mL/min/1.73m² for initiation 1
Additional Benefits for CKD Patients
If your patient has any degree of chronic kidney disease, empagliflozin provides substantial kidney protection beyond stone prevention. The 2024 BMJ guidelines strongly recommend SGLT2 inhibitors for CKD patients, showing reductions in kidney failure, cardiovascular mortality, and all-cause mortality 4. Recent 2025 data confirms empagliflozin reduces acute kidney injury risk by 20% and chronic kidney disease progression by 30% 5.
Clinical Bottom Line
Proceed with Jardiance without hesitation in patients with kidney stone history. Not only is it safe, but it may provide the added benefit of reducing future stone recurrence—a potential "two birds with one stone" scenario if the patient has diabetes, heart failure, or CKD as primary indications. The standard kidney stone prevention measures (adequate hydration to achieve >2L urine output daily) should still be maintained 6, but Jardiance adds no stone-related risk and likely provides additional protection.